All In Biotech

Drug Trial Radar · NCT07051915

The Holistic Study

Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) - a Pragmatic Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Sep 15, 2025

Primary completion

Jan 31, 2028

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Ostfold Hospital TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Oslo University Hospital; University Hospital, Akershus; Sykehuset i Vestfold HF; St. Olavs Hospital; Helse Stavanger HF; Sorlandet Hospital HF; University Hospital of North Norway; Haukeland University Hospital; Helse Nord-Trøndelag HF; Helse Fonna; Nordlandssykehuset HF
First posted
Jul 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase 3 study where eligible patients will be randomized 1:1 to one of two treatment strategies: receiving a thrombopoietin receptor agonist (Avatrombopag), or anti-CD20 (Rituximab).

Conditions

  • Thrombocytopenia Purpura

Interventions

  • AvatrombopagDrug

    Daily tablets

  • Rituximab (Arm B)Drug

    I.V.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of the oral TPO-RA, Avatrombopag, to RituximabTime frame: Assessed at week 28

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.